Neisserial OMV Vaccines
奈瑟氏菌 OMV 疫苗
基本信息
- 批准号:10588243
- 负责人:
- 金额:$ 20.19万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-03-26 至 2025-02-28
- 项目状态:未结题
- 来源:
- 关键词:AccelerationAdjuvantAntibiotic ResistanceAntigensBiological AssayChlamydiaClinical TrialsDataData ProtectionDatabasesDoseDrug Metabolic DetoxicationEffectivenessEpidemiologyEpitopesGeneticGoalsGonorrheaHealthHumanImmune SeraImmune responseImmunizationImmunizeImmunosuppressionIndividualInfectionInflammationIon ChannelIronLaboratoriesLicensingLipid AMeasuresMembraneMembrane ProteinsMethodsModelingMucous MembraneMusNeisseria gonorrhoeaeNeisseria meningitidisPathogenesisPharmaceutical PreparationsPreclinical TestingProteinsPublic HealthPublishingQualifyingQuality ControlRecombinantsRegimenReproductive Tract InfectionsResearchResearch PersonnelRiskRisk ReductionRouteSafe SexSafetySerogroup B Neisseria meningitidisSex CounselingStandardizationSurfaceTestingUniversitiesVaccinationVaccine AdjuvantVaccinesVesicleVirus-like particleWorkburden of illnessco-infectiondesignefflux pumpepidemiologic datagonorrhea vaccinein vivomanufacturabilitymouse modelnanodisknext generationnoveloverexpressionpre-clinical assessmentreproductive tractresistant straintoolvaccine candidatevaccine developmentvaccine efficacyvaccine evaluationvaccine platformvaccine-induced immunity
项目摘要
ABSTRACT
The goal of Project 2: “Neisserial outer membrane vesicle vaccines” within the Gonorrhea
Vaccine Cooperative Research Center (GV CRC) is to develop candidate Neisseria gonorrhoeae
(Ng) and Neisseria meningitidis (Nm) OMV vaccines that protect against gonorrhea. The premise
of this application is that an effective gonorrhea vaccine can be developed using neisserial OMVs
containing defined surface exposed, protective antigens. This premise is supported by exciting
new epidemiological evidence that serogroup B Nm OMVs can reduce the risk of gonorrhea and
preliminary data from our laboratories that show two different Nm OMV-based vaccines
accelerate clearance of Ng from experimentally infected mice. The Specific Aims of the
application are to: 1) Further develop a novel Nm OMV vaccine that demonstrates in vivo efficacy
against Ng, 2) Develop Ng OMV vaccines with increased expression of promising vaccine targets,
and 3) Develop next-generation Ng and, or Nm OMV vaccines consisting of OMVs combined with
nanodisc-displayed protein vaccines or Ng epitope-targeted virus-like-particle vaccines being
developed by other GV CRC investigators. OMVs will undergo standardized quality control for
structural integrity and composition and a rigorous pre-clinical assessment using state-of-the art
assays for measuring host immune responses and in vivo efficacy in mouse models of Ng lower
and upper reproductive tract (LRT, URT) infection. The most promising vaccines, defined by the
capacity to induce systemic and mucosal humoral and cellular immune responses and protect
against murine genital tract infection, will be selected for advancement to further pre-clinical
testing and clinical trials. We will also test the effect of licensed adjuvants on alleviating Ng-
induced immunosuppression of Ng OMV vaccine efficacy and utilize the database of immune
responses and in vivo protection data obtained from all candidate vaccines to define mechanisms
of vaccine-induced immunity.
摘要
项目2的目标:淋病内的“奈瑟球菌外膜囊泡疫苗”
疫苗合作研究中心(GV CRC)正在开发候选淋病奈瑟菌
(Ng)和预防淋病的脑膜炎奈瑟菌(Nm)OMV疫苗。前提
本申请的一个优点是可以使用奈瑟球菌OMV开发有效的淋病疫苗
含有确定的表面暴露的保护性抗原。这一前提得到了令人兴奋的支持
新的流行病学证据表明,血清型B Nm OMV可以降低淋病的风险,
我们实验室的初步数据显示,
加速Ng从实验感染的小鼠中的清除。的具体目标
本申请的目的是:1)进一步开发一种新的Nm OMV疫苗,
2)开发具有增加的有希望的疫苗靶标的表达的Ng OMV疫苗,
和3)开发下一代Ng和/或Nm OMV疫苗,其由OMV组合
纳米盘展示的蛋白质疫苗或Ng表位靶向的病毒样颗粒疫苗,
由其他GV CRC研究者开发。OMV将接受标准化质量控制,
结构完整性和组成,以及使用最先进技术进行严格的临床前评估
用于测量Ng降低小鼠模型中宿主免疫应答和体内功效的测定
和上生殖道(LRT,URT)感染。最有前途的疫苗,由
诱导全身和粘膜体液和细胞免疫应答并保护
针对鼠生殖道感染,将被选择用于进一步的临床前研究
测试和临床试验。我们还将测试许可的佐剂对减轻Ng-
诱导免疫抑制的Ng OMV疫苗效力和利用免疫数据库
从所有候选疫苗中获得的应答和体内保护数据,以确定机制
疫苗诱导的免疫力。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ann E. Jerse其他文献
Gonococcal PorB: a multifaceted modulator of host immune responses
淋球菌孔蛋白B:宿主免疫反应的多面调节因子
- DOI:
10.1016/j.tim.2023.10.002 - 发表时间:
2024-04-01 - 期刊:
- 影响因子:14.900
- 作者:
Rebekah A. Jones;Ann E. Jerse;Christoph M. Tang - 通讯作者:
Christoph M. Tang
emNeisseria gonorrhoeae/em Coinfection during emChlamydia muridarum/em Genital Latency Does Not Modulate Murine Vaginal Bacterial Shedding
淋病奈瑟菌/鼠衣原体生殖器潜伏期间的合并感染不会调节小鼠阴道细菌脱落
- DOI:
10.1128/spectrum.04500-22 - 发表时间:
2023-05-18 - 期刊:
- 影响因子:3.800
- 作者:
Delia Onorini;Cory Ann Leonard;Regenia Phillips Campbell;Barbara Prähauser;Theresa Pesch;Robert V. Schoborg;Ann E. Jerse;Bernadetta Tarigan;Nicole Borel - 通讯作者:
Nicole Borel
Ann E. Jerse的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Ann E. Jerse', 18)}}的其他基金
The Gonorrhea Vaccine Cooperative Research Center
淋病疫苗合作研究中心
- 批准号:
10362587 - 财政年份:2019
- 资助金额:
$ 20.19万 - 项目类别:
The Gonorrhea Vaccine Cooperative Research Center
淋病疫苗合作研究中心
- 批准号:
10588233 - 财政年份:2019
- 资助金额:
$ 20.19万 - 项目类别:
Continuing Preclinical Development of PPCM Vaginal Contraceptive MPT to IND
PPCM 阴道避孕药 MPT 至 IND 的持续临床前开发
- 批准号:
9889971 - 财政年份:2017
- 资助金额:
$ 20.19万 - 项目类别:
The Atlantic Coast Sexually Transmitted Infection Cooperative Research Center (AC
大西洋海岸性传播感染合作研究中心(AC
- 批准号:
9316484 - 财政年份:2014
- 资助金额:
$ 20.19万 - 项目类别:
The Atlantic Coast Sexually Transmitted Infection Cooperative Research Center (AC
大西洋海岸性传播感染合作研究中心(AC
- 批准号:
8769562 - 财政年份:2014
- 资助金额:
$ 20.19万 - 项目类别:
2014 International Pathogenic Neisseria Conference
2014年国际致病性奈瑟菌会议
- 批准号:
8785926 - 财政年份:2014
- 资助金额:
$ 20.19万 - 项目类别:
相似海外基金
Metachronous synergistic effects of preoperative viral therapy and postoperative adjuvant immunotherapy via long-term antitumor immunity
术前病毒治疗和术后辅助免疫治疗通过长期抗肿瘤免疫产生异时协同效应
- 批准号:
23K08213 - 财政年份:2023
- 资助金额:
$ 20.19万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Improving the therapeutic immunity of cancer vaccine with multi-adjuvant polymeric nanoparticles
多佐剂聚合物纳米粒子提高癌症疫苗的治疗免疫力
- 批准号:
2881726 - 财政年份:2023
- 资助金额:
$ 20.19万 - 项目类别:
Studentship
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
- 批准号:
10735090 - 财政年份:2023
- 资助金额:
$ 20.19万 - 项目类别:
Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) Assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trial
NSABP B-42 试验中内分泌治疗敏感性 (SET ER/PR) 测定的评估,用于预测延长辅助内分泌治疗持续时间的益处
- 批准号:
10722146 - 财政年份:2023
- 资助金额:
$ 20.19万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 20.19万 - 项目类别:
DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES
流感疫苗类 AS01 合成佐剂系统 SAS 的开发
- 批准号:
10935776 - 财政年份:2023
- 资助金额:
$ 20.19万 - 项目类别:
DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE
流感病毒疫苗小分子双佐剂体系的研制
- 批准号:
10935796 - 财政年份:2023
- 资助金额:
$ 20.19万 - 项目类别:
A GLYCOLIPID ADJUVANT 7DW8-5 FOR MALARIA VACCINES
用于疟疾疫苗的糖脂佐剂 7DW8-5
- 批准号:
10935775 - 财政年份:2023
- 资助金额:
$ 20.19万 - 项目类别:
Adjuvant Photodynamic Therapy to Reduce Bacterial Bioburden in High-Energy Contaminated Open Fractures
辅助光动力疗法可减少高能污染开放性骨折中的细菌生物负载
- 批准号:
10735964 - 财政年份:2023
- 资助金额:
$ 20.19万 - 项目类别:
Adjuvant strategies for universal and multiseasonal influenza vaccine candidates in the context of pre-existing immunity
在已有免疫力的情况下通用和多季节流感候选疫苗的辅助策略
- 批准号:
10649041 - 财政年份:2023
- 资助金额:
$ 20.19万 - 项目类别:














{{item.name}}会员




